Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00335452 · ClinicalTrials.gov registry record · Phase 3
Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 25,086
- Enrollment target
NCT00335452: Completed Phase 3 study, sponsored by Sanofi.
NCT00335452 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 25,086 participants, above the 770-participant average among 15,282 other Phase 3 trials with a reported enrollment target (3158% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00335452, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 25,086 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether a higher dosage of clopidogrel with aspirin (two doses) will decrease the risk of ischemic complications (cardiac death (CV death), myocardial infarction (MI), stroke) after a percutaneous coronary intervention (PCI).
Primary Outcome
The primary endpoint is the first occurrence of any of the following events: * Cardiovascular death (any death with a clear cardiovascular or unknown cause), * Myocardial Infarction (diagnosis of new Myocardial Infarction (MI) - nonfatal or fatal) * Stroke (presence of a new focal neurologic deficit thought to be vascular in origin, with signs or symptoms lasting more than 24 hours - nonfatal or fatal) reported between the randomization and Day 30 (inclusive), and validated by the blinded Even
Interventions
- DRUG Clopidogrel
- DRUG acetylsalicyclic acid (ASA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25,086 participants |
| Start Date | 2006-06 |
| Est. Completion | 2009-09 |
| Phase | Phase 3 |
What the finished NCT00335452 record still lists
NCT00335452 is an interventional study that assigns participants to a tested intervention. Its 25,086 participants enrollment target places it among the larger protocols in the corpus, above the 770-participant average among 15,282 other Phase 3 trials with a reported enrollment target (3158% higher).
The record links to 0 conditions, and to 2 interventions - of which Clopidogrel is the first listed.
NCT00335452 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00335452 about?
NCT00335452 is a clinical study titled "Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS". The purpose of this study is to evaluate whether a higher dosage of clopidogrel with aspirin (two doses) will decrease the risk of ischemic complications (cardiac death (CV death), myocardial infarction (MI), stroke) after a percutaneous coronary intervention (PCI).
What is the current status of trial NCT00335452?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 25,086 participants. The study started on 2006-06. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00335452?
The interventions under investigation include: Clopidogrel (DRUG), acetylsalicyclic acid (ASA) (DRUG).
Who is sponsoring clinical trial NCT00335452?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00335452's enrollment target sits among peer trials
25,086 9th of 2000 higher than 1,992 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04595201 · 25,000 participants
Clinical Follow-up of Pregnant Subjects Undergoing NIPT
- NCT04994015 · 25,000 participants
Parkinson's Foundation PD GENEration Genetic Registry
- NCT06589310 · 25,000 participants
Falcon Real World Evidence Registry
- NCT06773897 · 25,000 participants
Rutgers University Study of the Genetics of Breast Cancer.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia